The Impact of Hormone Replacement Therapy on the Pathophysiology of Peripheral Arterial Disease

European Journal of Vascular and Endovascular Surgery

Volumn 34, Issue 5, 2007, Pages 569-575

  Davies, R S M ^a   Vohra, R K ^a   Bradbury, A W ^a   Adam, D J ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Hormone replacement therapy; Peripheral vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; CONJUGATED ESTROGEN; DYDROGESTERONE PLUS ESTRADIOL; ELLESTE DUET; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE PLUS NORETHISTERONE; ESTRADIOL VALERATE PLUS NORGESTREL; ESTROGEN; EVORELL; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; MEVINOLIN; PLACEBO; PREMPAK; PROGESTERONE; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTERY DISEASE; ARTERY THROMBOSIS; ATHEROSCLEROSIS; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE COURSE; DRUG ANTAGONISM; DRUG MECHANISM; ENDOMETRIAL DISEASE; ENDOVASCULAR SURGERY; ESTROGEN THERAPY; FEMOROPOPLITEAL BYPASS; HORMONE SUBSTITUTION; HUMAN; INFORMATION RETRIEVAL; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; MEDLINE; MENOPAUSAL SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ATHEROSCLEROSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROGESTERONE;

EID: 34848852250     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2007.06.002     Document Type: Review

References (59)

1. Westendorp I.C., Veld B.A., Grobbee D.E., Pols H.A., Meijer W.T., Hofman A., et al. Hormone replacement therapy and peripheral arterial disease. The Rotterdam Study. Arch Intern Med 160 (2000) 2498-2502
2. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
3. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 288 1 (2002) 49-57
4. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Synder T.E., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 (2000) 522-529
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized controlled trial. JAMA 288 (2002) 321-333
6. Bots M.L., Mulder P.G., Hofman A., Van Es G.A., and Grobbee D.E. Reproducibility of carotid vessel wall thickness measurements: the Rotterdam Study. J Clin Epidemiol 47 (1994) 921-930
7. Hodis H.N., Mack W.J., Lobo R.A., Shoupe D., Sevanian A., Mahrer P.R., et al. Estrogen in the prevention of atherosclerosis. A randomized double-blind, placebo-controlled trial. Ann Intern Med 135 (2001) 939-953
8. Westendorp I.C., In'T Veld B.A., Bots M.L., Akkerhuis J.M., Hofman A., Grobbee D.E., et al. Hormone replacement therapy and intima-media thickness of the common carotid artery. The Rotterdam Study. Stroke 30 (1999) 2562-2567
9. Nabulsi A.A., Folsom A.R., Szklo M., White A., Higgins M., and Heiss G. No association of menopause and hormone replacement therapy with carotid artery intima-media thickness. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 94 (1996) 1857-1863
10. Mackey R.H., Kuller L.H., Sutton-Tyrrell K., Evans R.W., Holubkov R., and Matthews K.A. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study. Arch Intern Med 165 5 (2005 Mar 14) 510-515
11. Arora S., Veves A., Caballaro A.E., Smakowski P., and LoGerfo F.W. Estrogen improves endothelial function. Journal of Vascular Surgery 27 6 (1998) 1141-1147
12. Register T.C., Adams M.R., Golden D.L., and Clarkson T.B. Conjucated equine estrogen alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective remodelling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 18 (1998) 1164-1171
13. Thijs A., Coen D.A., and Stehouwer M.D. Changes of hemostatic variables during HRT. Semin Vasc Med 3 (2003) 85-92
14. Low G.D. Hormone replacement therapy: prothrombotic vs. protective effects. Pathophysiol Haemost Thromb 32 (2002) 329-332
15. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273 (1995) 199-208
16. Doukeits J.D., Gordon M., Johnston M., Julian J.A., Adachi J.R., and Ginsberg J.S. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. Thromb Res 99 (2000) 25-34
17. Herrington D. The HERS trial results: paradigms lost?. Ann Intern Med 131 (1999) 463-466
18. Psaty B.M., Smith N.L., Lemaitre R.N., Vos H.L., Heckbert S.R., LaCroix A.Z., et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 285 (2001) 906-913
19. British National Formulary September 2003; 6.4.1.1: 350-360.
20. Beral V., Banks E., and Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360 (2002) 942-944
21. Scarabin P.Y., Oger E., and Plu-Bureau G. EStrogen and ThromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362 9382 (2003) 428-432
22. Lieberman E.H., Gerhard M.D., Uehata A., Walsh B.W., Selwyn A.P., Ganz P., et al. Estrogen improves endothelium-dependent, flow-related vasodilatation in postmenopausal women. Ann Intern Med 121 (1994) 936-941
23. Anwaar I., Rendell M., Gottsater A., Lindgarde M., Hulthen U.L., and Mattiasson I. Hormone replacement therapy in healthy postmenopausal women. Effects on intraplatelet cyclic guanosine monophosphate, plasma endothelin-1 and neopterin. Journal of Internal Medicine 247 (2000) 463-470
24. Jonkela H., Dastidar P., and Rontu R. Effects of long-term oestrogen therapy versus combined hormone replacement therapy on nitric oxide-dependent vasomotor function. J Clin Endocrinol Metab 88 9 (2003) 4348-4354
25. Imthurn B., Rosselli M., Jaeger A.W., Keller P.J., and Dubey R.K. Differential effects of hormone-replacement therapy on endogenous nitric oxide (Nitrite/Nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 82 (1997) 388-394
26. Scuteri A., and Ferrucci L. Blood pressure, arterial function, structure and aging: the role of hormonal replacement therapy in postmenopausal women. J Clin Hypertens 5 (2003) 219-225
27. Teede H.J., Liang Y.L., Kotsopoulos D., Zoungas S., Cravent R., and McGrath B.P. A placebo- controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clin Endocrinol 55 5 (2001) 673-682
28. Hsia J., Simon J.A., Lin F., Applegate W.B., Vogt M.T., Hunninghake D., et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease. Circulation 102 (2000) 2228-2232
29. Humphrey L.L., Chan B.K., and Sox H.C. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 137 (2002) 273-284
30. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., and Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA 288 (2002) 872-881
31. Grady D., Rubin S.M., and Pettiti D.B. Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine 117 (1992) 1016-1037
32. Roussouw J.E. Hormone replacement therapy and cardiovascular disease. Current Opinion Lipidology 10 (1999 Oct) 429-434
33. Nissen S.E. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 96 (2005) 61-68
34. Collins R., Armitage J., Parish S., Sleight P., and Peto R. Heart Protection Study Collaborative Group. Effects of cholesterol lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
35. Aengevaeren W.R., Kroom A.A., Stalenhoef A.F., Uijen G.J., and Van der Werf T. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesteraemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 28 (1996) 1696-1704
36. Sherwin B.B., and Gelfand M.M. A prospective one year study on oestrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol 73 (1989) 759-766
37. Himmelamnn A., Svensson A., and Hansson L. Influence of sex on blood pressure and left ventricular mass in adolescents: the Hypertension in Pregnancy Offspring Study. J Hum Hypertens 8 (1994) 485-490
38. Salkeborn M. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 99 (1992) 821-828
39. Thompson S.G. The use of hormone replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health 43 (1989) 173-178
40. The long-term intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
41. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 8934 (1994) 1383-1389
42. Robinson J.G., Smith B., Maheshwari N., and Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46 (2005) 1855-1862
43. Beckman J.A., and Creager M.A. The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med 16 (2006) 156-162
44. Chambliss K.L., and Shaul P.W. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 23 (2002) 665-686
45. Daniel K.R., and Herrington D.M. Statin therapy in the heart and oestrogen/progestin replacement study. Minerva Ginecol 55 (2003) 209-215
46. Byington R.P., Evans G.W., Espeland M.A., Applegate W.B., Hunninghake D.B., Probstfield J., et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 100 (1999) 14-17
47. Andersson B. Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment. Drugs Aging 17 (2000) 399-410
48. Seely E.W., Walsh B.W., Gerhard M.D., and Williams G.H. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 33 (1999) 1190-1194
49. Cagnacci A., Rovati L., Zanni A., Malmusi S., Facchinetti F., and Volpe A. Physiological doses of estradiol decrease nocturnal blood pressure in normotensive postmenopausal women. Am J Physiol 276 (1999) H1355-H1360
50. Scuteri A., Bos A.J., Brant L.J., Talbot L., Lakatta E.G., and Fleg J.L. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med 135 (2001) 229-238
51. Redberg R.F., Masami N., and McElhinney D.B. Long-term oestrogen replacement therapy is associated with improved exercise capacity in postmenopausal women without known coronary artery disease. American Heart Journal 139 (2000) 739-744
52. Strano A., Hoppensteadt D., Walenga J.M., Fareed J., Sabba C., Berardi E., et al. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. Semin Thromb Hemost 22 Suppl. 1 (1996) 35-40
53. Timaran C.H., Stevens S.L., Grandas O.H., Freeman M.B., and Goldman M.H. Influence of hormone replacement therapy on the outcome of iliac angioplasty and stenting. J Vasc Surg 33 Suppl. 2 (2001) S85-S92
54. Timaran C.H., Stevens S.L., Grandas O.H., Piercy K.T., Freeman M.B., and Goldman M.H. Influence of hormone replacement therapy on graft patency after femoropopliteal bypass grafting. J Vasc Surg 32 (2000) 506-516 [516-8]
55. Royal College of Obstetricians and Gynaecologists. Hormone Replacement Therapy and Venous Thromboembolism (19) - Jan 2004. www.rcog.org.uk/clingov1
56. Hobbs S.D., Yapanis M., Burns P.J., Wilmink A.B., Bradbury A.W., and Adam D.J. Peri-operative myocardial injury in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg 29 (2005) 301-304
57. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., and Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345 (2001) 1243-1249
58. Schulman S.P., Thiemann D.R., Ouyang P., Chandra N.C., Schulman D.S., Reis S.E., et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol 39 (2002) 231-237
59. Falkeborn M., Persson I., Adami H.O., Bergstrom R., Eaker E., Lithell H., et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 99 (1992) 821-828